NasdaqGS - Nasdaq Real Time Price USD
OptiNose, Inc. (OPTN)
9.39
0.00
(0.00%)
At close: May 9 at 4:00:00 PM EDT
9.38
-0.01
(-0.11%)
After hours: May 9 at 4:00:09 PM EDT
Key Executives
Amounts are as of December 31, 2024 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Dr. Ramy A. Mahmoud M.D., M.P.H. | CEO & Director | 1.44M | -- | 1965 |
| Mr. Michael F. Marino Esq. | Chief Legal Officer & Corporate Secretary | 781.54k | -- | 1976 |
| Mr. Paul Spence | Chief Commercial Officer | 712.45k | -- | 1969 |
| Mr. P. Terence Kohler | Chief Financial Officer | -- | -- | -- |
| Mr. Anthony J. Krick | VP of Finance & Chief Accounting Officer | -- | -- | 1981 |
| Mr. Jonathan Neely | Vice President of Investor Relations & Business Development | -- | -- | -- |
| Ms. Karen E. Brophy | Chief Human Resources Officer & VP of Human Resources | -- | -- | 1963 |
OptiNose, Inc.
777 Township Line Road
Suite 300
Yardley, PA 19067
United States
- Sector:
- Healthcare
- Industry: Drug Manufacturers - Specialty & Generic
- Full Time Employees:
- 127
Description
OptiNose, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, throat, and allergy specialists. It offers XHANCE, a therapeutic product utilizing its proprietary exhalation delivery system (EDS) that delivers a topically acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps, as well as is in Phase III clinical trial for treatment of chronic sinusitis; and Onzetra Xsail, a powder EDS device. The company was founded in 2000 and is headquartered in Yardley, Pennsylvania.
Corporate Governance
OptiNose, Inc.’s ISS Governance QualityScore as of May 1, 2025 is 7. The pillar scores are Audit: 5; Board: 7; Shareholder Rights: 8; Compensation: 9.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Upcoming Events
May 12, 2025 at 12:30 PM UTC - May 16, 2025 at 12:30 PM UTC
OptiNose, Inc. Earnings Date
Recent Events
Related Tickers
LFCR Lifecore Biomedical, Inc.
6.97
+1.16%
ANIK Anika Therapeutics, Inc.
11.64
-21.03%
KMDA Kamada Ltd.
6.88
-1.57%
PBH Prestige Consumer Healthcare Inc.
87.30
+0.30%
AMRX Amneal Pharmaceuticals, Inc.
7.41
-0.67%
HCM HUTCHMED (China) Limited
14.21
-2.27%
AQS.V Aequus Pharmaceuticals Inc.
0.0050
0.00%
COLL Collegium Pharmaceutical, Inc.
28.89
+5.94%
KALY Kali, Inc.
0.0001
0.00%
HMPQ HempAmericana, Inc
0.0001
0.00%